Establishing the probable mechanism of L-dopa in Alzheimer's disease management

Acta Poloniae Pharmaceutica - Drug Research

Volumn 66, Issue 5, 2009, Pages 483-486

  Nivsarkar, Manish ^a   Banerjee, Aryamitra ^a  

^a B V PATEL PHARMACEUTICAL EDUCATION AND RESEARCH DEVELOPMENT PERD CENTRE   (India)

Author keywords

Aluminum; Alzheimer's disease; Entacapone; L DOPA

Indexed keywords

ALUMINUM; ENTACAPONE; LEVODOPA; LIPID; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; RESPIRATORY BURST; TISSUE INJURY;

ALUMINUM COMPOUNDS; ALZHEIMER DISEASE; ANIMALS; BRAIN; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; CHLORIDES; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; LEVODOPA; LIPID PEROXIDATION; NITRILES; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE;

EID: 70350512095     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Cotzias G.C., Miller S.T., Nicholson Jr. A.R., Maston W.H., Tang L.C.: Proc. Natl. Acad. Sci. USA 71, 2466 (1974).
2. Daxenbichler M.E., Van Etten C.H., Hallinan E.A., Earle F.R., Barclay A.S.: J. Med. Chem. 14, 463 (1971).
3. Parikh K.M., Doshi V.J., Sawant S.V., Salunkh U.B.: Indian Drugs 27, 353 (1990).
4. Apaydin H., Ertan S., Ozekmekci S.: Mov. Disord. 15, 164 (2000).
5. Gibson C.: Adv. Biol. Psychiat. 10, 4 (1983).
6. Spencer J.P., Jenner A., Butler J., Aruoma O.I., Dexter D.T., Jenner P., Halliwell B.: Free Radic. Res. 24, 95 (1996).
7. th ed., Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W. Eds., p. 506, McGraw-Hill, New York 1996.
8. Scatena R., Martorana G.E., Bottoni P., Botta G., Pastore P., Giardina B.: Expert Opin. Investig. Drugs 16, 59 (2007).
9. Ritchie K., Lovestone S.: Lancet 360, 1759 (2002).
10. Li J., Zhu M., Manning-Bog A.B., Di Monte D.A., Fink A.L.: FASEB J. 18, 962 (2004).
11. Storga D., Vrecko K., Birkmayer J.G., Reibnegger G.: Neurosci. Lett. 203, 29 (1996).
12. Ambree O., Richter H., Sachser N., Lewejohann L., et al.: Neurobiol. Aging 30, 1192 (2009).
13. Nivsarkar M., Banerjee A., Padh H.: Pharmacol. Rep. 60, 692 (2008).
14. Smith M.A., Hirai K., Nunomura A., Perry G.: Drug Dev. Res. 46, 26 (1999).
15. Nivsarkar M., Banerjee A., Shah D., Trivedi J., Patel M., Cherian B., Padh H.: Iranian Biomed. J. 10, 151 (2006).
16. Walton J.R.: J. Inorg. Biochem. 101, 1275 (2007).
17. Lipman J.J., Brill A.B., Som P., Jones K.W., Colowick S., Cholewa M.: Biol. Trace Elem. Res. 13, 43 (1987).
18. Lukiw W.J., Percy M.E., Kruck T.P.: J. Inorg. Biochem. 99, 1895 (2005).
19. Ogasawara Y., Ohata E., Sakamoto T., Ishii K., Takahashi H., Tanabe S.: Biol. Trace Elem. Res. 96, 191 (2003).
20. Okahwa H., Ohishi N., Yagi K.: J. Lipid Res. 19, 1053 (1978).
21. Marklund S., Marklund G.: Eur. J. Biochem. 47, 469 (1974).
22. de Lustig E.S., Serra J.A., Kohan S., Canziani G.A., Famulari A.L., Dominguez R.O.: J. Neurol. Sci. 115, 18 (1993).
23. Ahlskog J.E., Uitti R.J., Low P.A., Tyce G.M., Nickander K.K., Petersen R.C., Kokmen E.: Mov. Disord. 10, 566 (1995).
24. Lewis C., Ballinger B.R., Presly A.S.: Br. Med. J. 1978, 550.
25. Mohr E., Mendis T., Rusk I.N., Grimes J.D.: J. Psych. Neurosci. 19, 17 (1994).